Resistance Pattern among Uropathogens Isolated From Perimenopausal and Postmenopausal Patients Visiting Gynaecology Outpatient Department: A Single-Centric Observational Study in a Tertiary Care Teaching Hospital
OBJECTIVE: Urinary tract infections (UTIs) represent one of the most pervasive microbial afflictions among women, yet their incidence and severity escalate considerably in the perimenopausal and postmenopausal population due to profound estrogenic decline, altered vaginal microbiota, and age-related comorbid states. These endocrine and anatomical transformations engender a milieu conducive to microbial colonization, recurrent infections, and increasingly resistant uropathogenic strains. The clinical landscape is further complicated by the indiscriminate use of empiric antimicrobial therapy, which often lacks microbiological validation and contributes substantially to the burgeoning crisis of antimicrobial resistance (AMR). The emergence of multidrug-resistant (MDR) and extended-spectrum beta-lactamase (ESBL)-producing organisms in community-acquired UTIs now constitutes an urgent diagnostic and therapeutic challenge, necessitating pathogen-specific surveillance and tailored antimicrobial stewardship strategies—particularly in hormonally compromised females. Aims and Objectives: The primary objective of this study was to meticulously delineate the resistance patterns of uropathogens isolated from symptomatic perimenopausal and postmenopausal women with confirmed lower urinary tract infection. Secondary objectives included: 1.To characterize the etiological microbiological spectrum among the menopausal cohort. 2. To determine the prevalence of MDR and ESBL-producing organisms.3. To correlate resistance phenotypes with menopausal status, diabetic comorbidity, and recurrent infection profiles.4. To compare therapeutic outcomes between empirical versus culture-directed management strategies. Materials and Methods: This prospective, cross-sectional analytical study was conducted over a two-month period in the Departments of Pharmacology and Gynaecology at a tertiary academic hospital. A total of 100 eligible female patients aged between 42 and 65 years, clinically presenting with lower UTI symptoms and confirmed bacteriuria, were enrolled after strict application of inclusion and exclusion criteria. Midstream urine samples were collected under aseptic conditions, promptly cultured, and processed as per CLSI (2023) standards. Pathogen identification and antimicrobial susceptibility testing were performed using standard biochemical methods and Kirby-Bauer disc diffusion technique, with ESBL confirmation via combined disc methods. Data were captured in structured case record forms and analyzed using SPSS v25. Descriptive statistics, chi-square test, and t-tests were applied where appropriate, with p < 0.05 considered statistically significant. Ethical approval and informed consent were secured in adherence with the Declaration of Helsinki. Results: Out of the 100 patients enrolled, 42 were perimenopausal and 58 were postmenopausal. Culture positivity was documented in 72% of cases, of which Escherichia coli (62%) was the most frequently isolated pathogen. Multidrug resistance was observed in 61.1% of culture-positive cases, and ESBL production was detected in 54.2% of isolates—most notably among E. coli and Klebsiella spp... Postmenopausal women demonstrated significantly higher rates of both MDR (62%) and ESBL positivity (71.8%) compared to perimenopausal women. Diabetic patients (54%) exhibited disproportionately elevated resistance patterns, with MDR and ESBL rates of 68.5% and 63.0%, respectively. Patients managed with culture-guided therapy achieved superior clinical and microbiological cure rates (86.2%) and lower recurrence at 8 weeks (11.7%) compared to those treated empirically (recurrence: 35.6%). No severe adverse drug reactions were noted; treatment adherence was classified as good in 78% of patients. Conclusion: This study underscores the escalating prevalence of antimicrobial resistance among menopausal women with UTIs, particularly in the context of diabetes and postmenopausal status. The findings highlight the urgent necessity for individualized, culture-based therapeutic regimens and routine resistance surveillance to mitigate the clinical and public health implications of MDR and ESBL emergence. Empirical therapy, devoid of microbiological anchoring, is increasingly untenable in this vulnerable cohort, and must yield to precision-guided protocols to avert therapeutic failures and long-term morbidity. Such as literacy and healthcare access were not formally stratified.
KEY WORDS: Urinary Tract Infection (UTI), Perimenopausal Women, Postmenopausal Women, Antimicrobial Resistance (AMR), Multidrug-Resistant Organisms (MDR), Extended-Spectrum Beta-Lactamase (ESBL), Escherichia coli, Uropathogens, Culture-Guided Therapy, Empirical Antibiotic Therapy, Menopausal Immunomodulation, Diabetes Mellitus and UTI, Antibiotic Susceptibility Testing (AST), Microbiological Surveillance, Genitourinary Atrophy, CLSI Guidelines, Hormonal Influence on Infection, Midstream Urine Culture, Recurrent UTI, Pharmacological Stewardship.